60

Nanjing Well Pharmaceutical Co Ltd

603351 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

27.95CNY-0.25 (-0.89%)

Price History

Full chart

Market Stats

Previous Close28.20
Open28.21
Day Range27.90 – 28.68
52-Week Range21.90 – 30.80
Volume1.70M
Market Cap3.72B
P/E (TTM)24.09
Forward P/E0.00
EPS1.14
Dividend Yield2.18%
Beta0.13
50-Day Avg25.77
200-Day Avg26.19

About

Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China and internationally. The company offers excipients for injection, oral, and topical applications; and active pharmaceutical ingredients (API), such as polidocanol and polyethylene glycol 3350 API/polyethylene glycol 4000 API. It also provides biomaterial products; water-ethylene glycol fire resistant hydraulic fluid, biodegradable hydraulic fluid base oil, full synthetic hydraulic fluid and compressor base oil, vehicle air conditioning compressor base oil, ester base oil for refrigeration compressor, gear oil, gear oil synthetic ester additive, base oil, synthetic esters, additive of metal working oil, lubricity additive for metal working fluid, base oil and additives for rolling oil, ester type emulsifier, special emulsifier for knitting machine oil, self-emulsifying ester, polyether products, ether type nonionic surfactant, auxiliaries of POY and FDY, as well as base oil for grease, automotive engines, and transmissions. In addition, the company offers Yangzhou well and research institute products; and a-linolenic acid, methyl and ethyl linolenate, linoleic acid, methyl linoleate, ethyl linoleate, EPA ethyl ester, oleic acid, methyl and ethyl oleate, arachidonic acid, methyl arachidonate, arachidonic acid ethyl ester, DHA oil, nervonic acid, eicosenoic acid, palmitoleic acid, palmitoleic acid methyl ester, "-linolenic acid, and "-linolenic acid methyl and ethyl esters. The company was formerly known as Nanjing Well Pharmaceutical Co.,Ltd. and changed its name to Nanjing Well Pharmaceutical Group Co.,Ltd. in April 2020. Nanjing Well Pharmaceutical Group Co.,Ltd. was founded in 2000 and is based in Nanjing, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Renrong Wu
  • Employees718
  • HeadquartersBuilding 5, Xuzhuang Software Park, Nanjing, China, 210042, China
  • Websitehttps://www.wellnj.com

Leadership

  • Mr. Renrong WuChairman & CEO · b. 1963
  • Mr. Qunsong TangVP, Secretary of the Board of Directors & CFO · b. 1967
  • Mr. Zhengsong GaoDirector, VP & Chief Engineer · b. 1965
  • Mr. Xinguo ChenDirector & VP · b. 1968
  • Mr. Jianguo ZouVice President · b. 1963
  • Yi YangAccounting Supervisor

Financials

Income Statement

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue527.60M498.69M558.44M694.11M801.45M880.76M736.06M1.04B1.11B1.16B1.30B1.34B
Growth (%)--5.48%+11.98%+24.29%+15.46%+9.90%-16.43%+41.61%+6.59%+4.03%+12.19%+2.95%
Cost of Revenue407.14M353.30M352.27M474.31M571.91M599.60M513.45M762.68M810.66M842.97M938.49M955.04M
Gross Profit120.46M145.39M206.17M219.80M229.54M281.16M222.62M279.63M300.36M312.87M358.26M380.00M
Gross Margin22.83%29.15%36.92%31.67%28.64%31.92%30.24%26.83%27.03%27.07%27.63%28.46%
Operating Expense67.91M73.78M96.46M93.90M101.90M123.99M103.70M159.87M187.13M191.09M185.91M192.47M
Operating Income52.55M71.61M109.71M125.90M127.64M157.16M118.91M119.76M113.23M121.78M172.35M187.53M
Operating Margin9.96%14.36%19.65%18.14%15.93%17.84%16.16%11.49%10.19%10.54%13.29%14.05%
EBITDA-479.51K-331.27K-6.65M155.03M164.57M193.20M157.68M166.04M189.02M205.02M293.22M316.04M
EBITDA Margin-0.09%-0.07%-1.19%22.33%20.53%21.94%21.42%15.93%17.01%17.74%22.61%23.67%
Net Income44.83M60.67M85.03M107.43M111.81M128.11M100.45M101.37M95.03M112.20M146.42M150.97M
Net Income Margin8.50%12.17%15.23%15.48%13.95%14.55%13.65%9.73%8.55%9.71%11.29%11.31%
R&D15.73M15.17M17.57M23.28M24.70M32.91M36.59M41.46M53.87M55.64M71.56M81.53M
R&D as % of Total Revenue2.98%3.04%3.15%3.35%3.08%3.74%4.97%3.98%4.85%4.81%5.52%6.11%
Interest Expense8.11M8.75M5.71M3.82M5.58M5.02M5.06M7.64M12.58M15.52M14.30M10.68M
Interest Expense % of Total Revenue1.54%1.76%1.02%0.55%0.70%0.57%0.69%0.73%1.13%1.34%1.10%0.80%

Balance Sheet

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets419.30M487.50M600.23M725.52M808.20M1.46B1.64B1.84B2.14B2.28B2.38B2.59B
Total Liabilities178.94M193.01M156.25M192.73M193.59M217.06M336.75M456.01M655.76M686.22M672.72M791.01M
Total Equity240.00M294.15M443.61M532.80M614.61M1.24B1.30B1.38B1.48B1.58B1.70B1.80B
Cash25.36M24.11M73.34M75.73M40.44M180.93M75.56M66.26M99.83M157.55M247.20M423.87M
Total Debt107.50M115.53M62.33M85.00M94.76M102.22M116.27M199.89M426.06M486.96M423.52M-
Net Debt82.14M91.42M-11.01M9.27M54.32M-78.71M40.71M133.63M326.23M329.41M176.32M104.47M

Cash Flow

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow74.62M81.14M128.18M71.27M63.76M129.69M93.30M-11.54M108.99M120.24M221.79M238.24M
Investing Cash Flow-88.54M-72.32M-69.80M-62.75M-76.43M-495.69M-165.44M-67.97M-237.68M-67.84M-70.48M-
Financing Cash Flow2.53M-6.85M-3.99M-3.11M-24.63M508.91M-32.60M70.56M161.20M4.79M-63.03M-
Capital Expenditure88.54M76.92M69.31M63.35M76.95M120.62M282.44M235.62M233.90M73.07M51.46M52.18M
Free Cash Flow-13.93M4.22M58.87M7.92M-13.19M9.08M-189.13M-247.16M-124.91M47.17M170.34M186.07M
Dividends Paid13.46M14.06M52.14M21.42M30.00M40.00M42.00M39.20M40.64M53.41M55.47M64.89M
FCF to OCF-18.66%5.20%45.93%11.11%-20.69%7.00%-202.71%2142.34%-114.61%39.23%76.80%78.10%
Dividend Paid to FCF-96.66%333.16%88.56%270.40%-227.42%440.59%-22.21%-15.86%-32.54%113.23%32.56%34.87%

Earnings

Report DateJan 14, 2019Apr 25, 2019Aug 19, 2019Oct 28, 2019Dec 31, 2019Apr 28, 2020Aug 19, 2020Oct 23, 2020Dec 31, 2020Apr 26, 2021Jul 29, 2021Oct 28, 2021Dec 31, 2021Apr 18, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Apr 24, 2023
EPS Estimate0.00-----------------
EPS Actual0.500.400.400.360.140.130.190.140.190.190.230.210.130.130.250.140.120.20
Surprise------------------
Timing-After-hoursAfter-hoursPre-market-Pre-marketAfter-hoursPre-market-Pre-marketPre-marketPre-market-Pre-market---Pre-market

Key Statistics & Ratios

Market Cap3.72B
Enterprise Value3.93B
Trailing P/E24.09
Forward P/E0.00
Price / Sales2.65
Price / Book2.09
EPS1.14
Book Value13.21
Revenue (TTM)1.40B
Gross Profit (TTM)389.67M
EBITDA305.55M
Profit Margin11.06%
Operating Margin12.64%
Return on Equity8.70%
Return on Assets4.64%
Shares Outstanding135.44M
Shares Float56.33M
Beta0.13
Dividend Yield2.18%
Dividend Rate0.60
Payout Ratio52.63%

Dividends

20231×
0.28Jun 8, 2023
20221×
0.30Jun 13, 2022
20211×
0.30May 25, 2021
20201×
0.45May 27, 2020
20191×
0.43May 28, 2019

Stock Splits

  • May 27, 20207:5
  • May 28, 20197:5